Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
AssigneeNeurocrine Biosciences, Inc.
InventorsLawrence Steinman, Nicholas Ling, Paul J. Conlon, Amitabh Gaur
Life of this patent
Estimating the term…
Abstract
Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.
Claims11
A peptide analogue comprising amino acid residues 87-99 of human myelin basic protein, wherein lysine at position 91 is altered to another amino acid.
A method of treating multiple sclerosis, comprising administering to a patient a therapeutically effective amount of a pharmaceutical composition comprising peptide analogue comprising amino acid residues 87-99 of myelin basic protein, wherein the L-lysine residue at position 91 is replaced by another amino acid, in combination with a physiologically acceptable carrier or diluent.
Dependencies are inferred from the claim text.